Elicio Therapeutics
Biotechnology ResearchMassachusetts, United States11-50 Employees
Elicio Therapeutics, Inc., listed on Nasdaq as ELTX, is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, employing 11-50 people and focused on developing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. The company uses Amphiphile technology designed to enhance education, activation and amplification of cancer-specific T cells relative to conventional vaccination strategies, with the goal of promoting durable cancer immunosurveillance. Its lead program, ELI-002, is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately 25% of solid tumors, and is being studied in a randomized trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy and remain at high risk of relapse; the program has also been evaluated in mKRAS-positive colorectal cancer in Phase 1 studies. Results from the AMPLIFY-201 Phase 1 trial presented at the ESMO Immuno-Oncology Congress 2024 noted that median overall survival in the CRC subset had not been reached after a median follow-up of 23.2 months, and complete clearance of ctDNA was observed in three of five CRC patients. Elicio plans to expand ELI-002 to additional indications and maintains an upstream pipeline of off-the-shelf cancer vaccines, including ELI-007 and ELI-008 targeting BRAF-driven cancers and p53 hotspot mutations.
1-888-653-2347 
support@leadiq.com 
